MNMD
Definium Therapeutics, Inc.
NASDAQ: MNMD
$23.02-0.53 (-2.25%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$6.34 – $26.25
Avg Volume2.5M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$23.02+141.6%
Pipeline
Drug candidates sponsored by Definium Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | MM120 (LSD D-Tartrate) | Generalized Anxiety Disorder+1 more | Active, not recruiting | 2026-11 | 3 | |
| Phase 3 | DT120 | Major Depressive Disorder | Recruiting | 2027-09 | 1 | |
| Phase 2 | MM120 | Anxiety Generalized+2 more | Completed | 2023-11-06past | 2 | |
| Phase 2 | DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Autism Spectrum Disorder+1 more | Recruiting | 2027-08 | 1 | |
| Phase 1 | 18-MC Compound | Addiction | Completed | 2021-12-13past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for MNMD. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.